Ultramodern treatments for malignant hepatocellular carcinoma (HCC) in clinics are ineffective and frequently produce impaired adherence from patients. Due to poor therapeutic efficiency and significant systemic side effects, we coupled chemo-photothermal targeted treatment for hepatocellular carcinoma (HCC) within a novel, versatile drug delivery system to overcome these issues. Targeted nanoparticle treatment also improves the efficacy of cancer therapy. Peptides are peculiarly well-suited as targeting moieties, with the powerful avidity. To achieve optimal targeting efficiency, potent peptide exhibit on nanostructures requires ideal development. In spite of its strong affinity for the tumor marker αVβ3 integrin receptor, the cyclo(Arg-Gly-Asp-D-Phe-Lys) (cRGD) peptide has gained widespread use. To achieve targeted chemo-photothermal treatment and near-infrared (NIR)/pH-responsive drug release, we construct a cRGD peptide-conjugated quercetin (QT) drug in the present investigation. This drug can be assembled into molybdenum selenide (MoSe2) coated zinc oxide (MoSe2/ZnO-PEG-QT-cRGD) nanocomposites (NCs). MoSe2/ZnO-PEG-QT-cRGD NCs were synthesized and characterized using UV–Vis, FT-IR, XRD, FE-SEM, and DLS analyses. The nanocomposites exhibited quasi-spherical morphology with an average hydrodynamic diameter of ∼158 nm (PDI 0.22), showed high drug loading efficiency (77 %), and demonstrated pH- and NIR-sensitive QT release, with excellent photothermal conversion capacity. The MoSe2/ZnO-PEG-QT-cRGD NCs that evolved were biocompatible, as shown by the MTT experiment. In vitro and in vivo findings indicated significantly enhanced therapeutic efficacy against Hep3B cells under NIR irradiation compared with non-targeted NCs. Therefore, this investigation may provide an innovative model for cancer detection and therapy, and findings may surely assist in enhancing the quality of life for cancer patients.
扫码关注我们
求助内容:
应助结果提醒方式:
